BiotechTube

LY3650150 + Placebo + Standard therapy for INCS

Phase 3Recruiting
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Perennial Allergic Rhinitis (PAR)

Conditions

Perennial Allergic Rhinitis (PAR)

Trial Timeline

Apr 26, 2024 → Oct 1, 2028

NCT ID
NCT06339008

About LY3650150 + Placebo + Standard therapy for INCS

LY3650150 + Placebo + Standard therapy for INCS is a phase 3 stage product being developed by Eli Lilly for Perennial Allergic Rhinitis (PAR). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06339008. Target conditions include Perennial Allergic Rhinitis (PAR).

What happened to similar drugs?

14 of 20 similar drugs in Perennial Allergic Rhinitis (PAR) were approved

Approved (14) Terminated (1) Active (6)
✅ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
✅Budesonide + PlaceboAstraZenecaApproved
✅Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
✅Placebo + Montelukast + Fluticasone propionateMerckApproved
✅montelukast + placeboMerckApproved
✅loratadine + loratadine + loratadineMerckApproved
✅Placebo nasal spray + Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ) + Placebo nasal spray + Claritin® SyrupSanofiApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06338995Phase 3Recruiting
NCT06339008Phase 3Recruiting

Competing Products

20 competing products in Perennial Allergic Rhinitis (PAR)

See all competitors
ProductCompanyStageHype Score
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
43
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
40
ciclesonide + mometasoneSumitomo PharmaPhase 3
40
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
ciclesonide HFA 160 μgSumitomo PharmaPhase 3
40
Budesonide + PlaceboAstraZenecaApproved
43
Ciclesonide + PlaceboAstraZenecaPhase 3
40
CiclesonideAstraZenecaPhase 3
40
CiclesonideAstraZenecaPhase 3
40
Ciclesonide nasal + PlaceboAstraZenecaPhase 3
40
Ciclesonide + PlaceboAstraZenecaPhase 3
40
Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
43
CiclesonideAstraZenecaPhase 3
40
MK-8237 tablets + Placebo tablets + Rescue Medication: Self-Injectable Epinephrine + Rescue Medication: Loratadine tablets + Rescue Medication: Olopatadine ophthalmic drops + Rescue Medication: Mometasone furoate nasal sprayMerckPhase 3
40
Placebo + Montelukast + Fluticasone propionateMerckApproved
35
montelukast + placeboMerckApproved
43
MK-8237 6 DU + MK-8237 12 DU + PlaceboMerckPhase 1
29
loratadine + loratadine + loratadineMerckApproved
43